NEW DELHI: Dalmia Healthcare on Thursday said it has started clinical trials to evaluate the efficacy and safety of its polyherbal combination 'Astha-15' for treatment of COVID-19.
All regulatory guidelines will be followed to conduct the multi-centric, Phase III clinical trials, the Dalmia Group firm said in a statement.
"We are conducting human trials of our highly efficient ayurvedic composition which can potentially help in curing COVID-19 patients," Dalmia Group of Companies Chairman Sanjay Dalmia said.
The polyherbal combination by the company has previously undergone a randomised double-blind, placebo-controlled study on patients in a speciality government hospital in Chennai, the statement said.
As per the study, the drug acts as a bronchodilator, decongestant, anti-inflammatory, lung detoxifier and did not show any side-effects, it added.
All regulatory guidelines will be followed to conduct the multi-centric, Phase III clinical trials, the Dalmia Group firm said in a statement.
"We are conducting human trials of our highly efficient ayurvedic composition which can potentially help in curing COVID-19 patients," Dalmia Group of Companies Chairman Sanjay Dalmia said.
The polyherbal combination by the company has previously undergone a randomised double-blind, placebo-controlled study on patients in a speciality government hospital in Chennai, the statement said.
As per the study, the drug acts as a bronchodilator, decongestant, anti-inflammatory, lung detoxifier and did not show any side-effects, it added.
(Catch all the Business News, Breaking News Budget 2024 News, Budget 2024 Live Coverage, Events and Latest News Updates on The Economic Times.)
...moreDownload The Economic Times News App to get Daily Market Updates & Live Business News.
Read More News on
(Catch all the Business News, Breaking News Budget 2024 News, Budget 2024 Live Coverage, Events and Latest News Updates on The Economic Times.)
...moreDownload The Economic Times News App to get Daily Market Updates & Live Business News.